Stocktoria
Eledon Pharmaceuticals, Inc. ELDN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-09-17
Eledon Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $66.3M | $52.0M | $30.3M | $27.1M | $23.7M |
| Operating income | — | — | -$43.0M | -$88.4M | -$36.9M |
| Income tax | $35,000 | $431,000 | $0 | $0 | -$2.4M |
| Net income | -$45.6M | -$36.2M | -$116.5M | -$88.0M | -$34.5M |
| EPS (diluted) | $-0.52 | $-0.66 | $-4.73 | $-6.16 | $-2.33 |
| Operating cash flow | -$62.3M | -$47.3M | -$39.5M | -$28.4M | -$28.9M |
| Cash & equivalents | $22.8M | $20.5M | $4.6M | $56.4M | $84.8M |
| Total assets | $169.0M | $177.4M | $89.1M | $92.8M | $170.5M |
| Total liabilities | $32.2M | $59.3M | $81.9M | $8.6M | $6.6M |
| Shareholders' equity | $81.1M | $62.4M | -$48.5M | $84.2M | $164.0M |
Source: SEC EDGAR filings · CIK 0001404281 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.